We treated a panel of ten ovarian cancer cell lines (including five HGSOC with CCNE1 amplification) with either INX-315 or palbociclib for six days, allowing for multiple doubling times before assessment of cell viability. This evidence concerns the gene CCNE1 and ovarian carcinoma.